Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,836 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Psychosis Clear all
Completed Not applicable Interventional Results available

Improving Accessibility and Personalization of CR for Schizophrenia

NCT03576976
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Cognitive Remediation
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Brooklyn, New York • New York, New York • Orangeburg, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Oct 19, 2026, 11:46 PM EDT
Not yet recruiting Not applicable Interventional

LIFU Effects & Outcomes: Mechanisms Evaluating Striatal Systems Imaging (LEO MESSI)

NCT07710989
View directory record Official record
Conditions
Schizophrenia, Auditory Hallucinations
Interventions
LIFU
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 19, 2026, 11:46 PM EDT
Completed Phase 2Phase 3 Interventional

Adjunctive Treatment for Decreasing Symptoms of Schizophrenia

NCT00222235
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
d-cycloserine, glycine, placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 54 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Glen Oaks, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 19, 2026, 11:46 PM EDT
Completed Not applicable Interventional

Computer-Aided Learning for Managing Stress

NCT02531243
View directory record Official record
Conditions
Psychosis
Interventions
CALMS
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
12 Years to 30 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 19, 2026, 11:46 PM EDT
Terminated Phase 2 Interventional

Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia

NCT05182476
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Luvadaxistat
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
33
States / cities
Phoenix, Arizona • Bentonville, Arkansas • Bryant, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 19, 2026, 11:46 PM EDT
Completed Not applicable Interventional Results available

Cognitive Behavioral Suicide Prevention for Psychosis: Aim 2

NCT05345184
View directory record Official record
Conditions
Suicide, Psychosis
Interventions
Cognitive Behavioral Suicide Prevention for psychosis (CBSPp), Services as Usual (SAU)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 19, 2026, 11:46 PM EDT
Completed Phase 1 Interventional

A Trial of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolar I Disorder

NCT03854409
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Little Rock, Arkansas • Garden Grove, California • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 19, 2026, 11:46 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

NCT05511363
View directory record Official record
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
KarXT, Placebo
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
55 Years to 90 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
59
States / cities
Homewood, Alabama • Phoenix, Arizona • Encino, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 19, 2026, 11:46 PM EDT
Completed Not applicable Interventional Results available

Impact of Inflammation on Reward Circuits, Motivational Deficits and Negative Symptoms in Schizophrenia

NCT03818516
View directory record Official record
Conditions
Schizophrenia
Interventions
Oral Glucose Tolerance Test (OGTT)
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 59 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 19, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Results available

Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders

NCT01720316
View directory record Official record
Conditions
Schizo-affective Disorder, Bipolar Disorder
Interventions
Glycine, placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 19, 2026, 11:46 PM EDT
Completed No phase listed Observational

The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels

NCT01385709
View directory record Official record
Conditions
Bipolar Affective Disorders, Cyclothymic Disorder, Schizoaffective Disorder, Major Depressive Disorder, Dysthymic Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Posttraumatic Stress Disorder, Premenstrual Dysphoric Disorder, Social Anxiety Disorder
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2017 · Synced Oct 19, 2026, 11:46 PM EDT
Completed Not applicable Interventional

Survivors of Sex Trafficking: Occupation-Based Interventions for Executive Functioning

NCT03611998
View directory record Official record
Conditions
Sex Trafficking, Mental Disorder
Interventions
Occupation-based programming
Behavioral
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
19 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 3, 2018 · Synced Oct 19, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia

NCT06572449
View directory record Official record
Conditions
Schizophrenia
Interventions
KarXT
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
6
States / cities
Los Alamitos, California • Riverside, California • Hollywood, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 19, 2026, 11:46 PM EDT
Completed Not applicable Interventional

Effect of High-Dose B-Complex Vitamins on the Symptoms of Schizophrenia

NCT00403247
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Capsule with folate, Vitamin B12 & pyridoxine, placebo
Dietary Supplement · Other
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2007 · Synced Oct 19, 2026, 11:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder

NCT04030143
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
19
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Bellflower, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 19, 2026, 11:46 PM EDT
Completed Phase 1 Interventional Results available

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

NCT06319170
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Olanzapine Extended Release, Olanzapine Immediate Release
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Los Alamitos, California • Hollywood, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 19, 2026, 11:46 PM EDT
Completed Phase 4 Interventional

Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence

NCT00215579
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Depot Risperidone Microsphere (Consta)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Butner, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 19, 2026, 11:46 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Memantine Augmentation of Targeted Cognitive Training in Schizophrenia

NCT04857983
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 19, 2026, 11:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Modulating Human Cortical Plasticity With Transcranial Electrical Stimulation

NCT03114488
View directory record Official record
Conditions
Healthy, Schizophrenia
Interventions
tDCS
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 50 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 19, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia

NCT04268303
View directory record Official record
Conditions
Agitation, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Schizophreniform Disorders
Interventions
Sublingual film containing dexmedetomidine (BXCL501), Placebo Film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
15
States / cities
Little Rock, Arkansas • Cerritos, California • Culver City, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 19, 2026, 11:46 PM EDT
Not listed Not applicable Interventional

Minocycline Augmentation in Schizophrenia

NCT01561742
View directory record Official record
Conditions
Schizophrenia
Interventions
Minocycline, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 35 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Oct 19, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.

NCT02281773
View directory record Official record
Conditions
Schizophrenia
Interventions
BI 409306 100 mg QD, BI 498306 50 mg QD, Placebo, BI 498306 25 mg QD, BI 409306 10 mg QD
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Little Rock, Arkansas • Cerritos, California • Garden Grove, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 19, 2026, 11:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Electroconvulsive Therapy in Clozapine Refractory Schizophrenia

NCT00042224
View directory record Official record
Conditions
Schizophrenia
Interventions
Electroconvulsive Therapy (ECT), Clozapine
Procedure · Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 19, 2026, 11:46 PM EDT